Cargando…

Outcomes and molecular profile of oligomonocytic CMML support its consideration as the first stage in the CMML continuum

Patients with oligomonocytic chronic myelomonocytic leukemia (OM-CMML) are currently classified according to the 2017 World Health Organization myelodysplastic syndromes classification. However, recent data support considering OM-CMML as a specific subtype of chronic myelomonocytic leukemia (CMML),...

Descripción completa

Detalles Bibliográficos
Autores principales:	Calvo, Xavier, Roman-Bravo, David, Garcia-Gisbert, Nieves, Rodriguez-Sevilla, Juan Jose, Garcia-Avila, Sara, Florensa, Lourdes, Gibert, Joan, Fernández-Rodríguez, Concepción, Salido, Marta, Puiggros, Anna, Espinet, Blanca, Colomo, Luis, Bellosillo, Beatriz, Ferrer, Ana, Arenillas, Leonor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Myeloid Neoplasia
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278296/ https://www.ncbi.nlm.nih.gov/pubmed/35709473 http://dx.doi.org/10.1182/bloodadvances.2022007359

Ejemplares similares

Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy
por: Schnegg-Kaufmann, Annatina S., et al.
Publicado: (2023)

Molecular and cytogenetic characterization of myelodysplastic syndromes in cell-free DNA
por: Garcia-Gisbert, Nieves, et al.
Publicado: (2022)

Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions
por: Valent, Peter, et al.
Publicado: (2019)

Mouse Models of CMML
por: Belotserkovskaya, Ekaterina, et al.
Publicado: (2021)

Leukemic Involvement Is a Common Feature in Waldenström Macroglobulinemia at Diagnosis
por: Montesdeoca, Sara, et al.
Publicado: (2023)

Combined GLUT1 and OXPHOS inhibition eliminates acute myeloid leukemia cells by restraining their metabolic plasticity
por: Rodriguez-Zabala, Maria, et al.
Publicado: (2023)

Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD
por: Pemmaraju, Naveen, et al.
Publicado: (2022)

Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1
por: Oñate, Guadalupe, et al.
Publicado: (2022)

Engraftment characterization of risk-stratified AML in NSGS mice
por: Díaz de la Guardia, Rafael, et al.
Publicado: (2021)

Evaluation of 4 prognostic indices in follicular lymphoma treated in first line with immunochemotherapy
por: Rodríguez-Sevilla, Juan Jose, et al.
Publicado: (2022)

Defining the transcriptional control of pediatric AML highlights RARA as a superenhancer-regulated druggable dependency
por: Perez, Monika W., et al.
Publicado: (2021)

Prognostic factors and survival in chronic myelomonocytic leukaemia (CMML).
por: Stark, A. N., et al.
Publicado: (1987)

Transformation of CMML to AML presenting with acute kidney injury
por: DeBoer, Rebecca, et al.
Publicado: (2020)

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML
por: Issa, Ghayas C., et al.
Publicado: (2022)

Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity
por: Bazinet, Alexandre, et al.
Publicado: (2023)

European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol
por: Bataller, Alex, et al.
Publicado: (2022)

Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia
por: Niu, Xiaojia, et al.
Publicado: (2021)

Calcitonin receptor‐like (CALCRL) is a marker of stemness and an independent predictor of outcome in pediatric AML
por: Angenendt, Linus, et al.
Publicado: (2021)

Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies
por: Stengel, Anna, et al.
Publicado: (2021)

A geno-clinical decision model for the diagnosis of myelodysplastic syndromes
por: Radakovich, Nathan, et al.
Publicado: (2021)

Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia
por: Wakita, Satoshi, et al.
Publicado: (2022)

Transcriptomic analysis reveals proinflammatory signatures associated with acute myeloid leukemia progression
por: Stratmann, Svea, et al.
Publicado: (2022)

An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia
por: Ragaini, Simone, et al.
Publicado: (2022)

Transcription factor MEF2D is required for the maintenance of MLL-rearranged acute myeloid leukemia
por: Zhao, Lianzhong, et al.
Publicado: (2021)

A CIBERSORTx-based immune cell scoring system could independently predict the prognosis of patients with myelodysplastic syndromes
por: Wang, Yu-Hung, et al.
Publicado: (2021)

A clinically applicable gene expression–based score predicts resistance to induction treatment in acute myeloid leukemia
por: Moser, Christian, et al.
Publicado: (2021)

The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML
por: Heikamp, Emily B., et al.
Publicado: (2022)

PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia
por: Goswami, Swagata, et al.
Publicado: (2022)

CAMK2G is identified as a novel therapeutic target for myelofibrosis
por: Miyauchi, Masashi, et al.
Publicado: (2022)

Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study
por: Middeke, Jan M., et al.
Publicado: (2022)

Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia
por: Fobare, Sydney, et al.
Publicado: (2022)

Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy
por: Versluis, Jurjen, et al.
Publicado: (2022)

TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML
por: Weinberg, Olga K., et al.
Publicado: (2022)

Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition
por: Maslah, Nabih, et al.
Publicado: (2022)

Changes in body mass index, weight, and height in children with acute myeloid leukemia and the associations with outcome
por: Iijima, Mayuko, et al.
Publicado: (2022)

Historical expectations with DNA methyltransferase inhibitor monotherapy in MDS: when is combination therapy truly “promising”?
por: Brunner, Andrew M., et al.
Publicado: (2022)

Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML
por: Martelli, Maria Paola, et al.
Publicado: (2021)

ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol
por: Buccisano, Francesco, et al.
Publicado: (2022)

Clofarabine with topotecan, vinorelbine, and thiotepa reinduction regimen for children and young adults with relapsed AML
por: Ramaswamy, Kavitha, et al.
Publicado: (2022)

SORT1/LAMP2-mediated extracellular vesicle secretion and cell adhesion are linked to lenalidomide resistance in multiple myeloma
por: Yamamoto, Tomofumi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7gu8a1qgt1dvde9v247bt1bdui